NCI-H1666 Xenograft Model Service for NSCLC

The NCI-H1666 xenograft model represents a rare bronchoalveolar carcinoma platform harboring a BRAF G466V class II activating mutation and ATM alterations, offering a distinctive preclinical substrate for evaluating HSP90-directed, SHP2-targeted, and BRAF/MEK combination strategies in a wild-type EGFR and KRAS background. Alfa Cytology leverages this molecularly characterized cell line—paired with authenticated banking, optimized implantation protocols, and integrated pharmacodynamic analysis—to advance your preclinical programs targeting non-canonical MAPK-driven lung adenocarcinoma.

Overview of NCI-H1666 Xenograft Model for NSCLC

The NCI-H1666 cell line was established in June 1987 by A.F. Gazdar and J.D. Minna at the National Cancer Institute from pleural effusion metastatic cells of a 50-year-old Caucasian female non-smoker diagnosed with bronchoalveolar carcinoma, a subtype of lung adenocarcinoma characterized by growth along alveolar septa without stromal invasion. The donor patient had received prior radiation therapy, a clinical history that may have influenced the genomic landscape of the derived line. Genetically, NCI-H1666 carries a BRAF G466V mutation, a class II activating alteration that signals as BRAF dimers independent of RAS input, and concurrently harbors an ATM mutation that has been functionally linked to exceptional sensitivity to MEK inhibitors such as trametinib. Both EGFR and KRAS remain wild-type, distinguishing this model from the majority of oncogene-driven NSCLC lines and positioning it as an ideal platform for evaluating therapies directed at class II BRAF mutants and downstream MAPK effectors.

Fig 1. In NCI-H1666 cells, INCB3619 combined with paclitaxel synergistically induced apoptosis, providing the mechanistic basis for the ADAM-inhibitor combination strategies evaluated in the accompanying in vivo xenograft models. (Zhou, Bin-Bing S., et al., 2006)

In immunodeficient hosts, NCI-H1666 demonstrates reliable tumorigenicity with robust engraftment when 5×10⁶ cells are implanted subcutaneously. Tumors become palpable within 10–14 days and progress with consistent kinetics. Preclinical validation has demonstrated that NCI-H1666 xenografts are profoundly sensitive to the HSP90 inhibitor ganetespib, with treated tumors exhibiting 12% regression under weekly dosing at 150 mg/kg. The model also displays marked sensitivity to the SHP2 inhibitor RMC-4550 (GI₅₀ 304 nM) and to the EGFR-targeted antibody-drug conjugate HTI-1511, reflecting its dependence on receptor tyrosine kinase signaling and chaperone-mediated protein homeostasis. These properties render the NCI-H1666 xenograft an indispensable tool for preclinical evaluation of HSP90-directed therapy, SHP2 inhibition, and rational combination regimens in a molecularly defined bronchoalveolar carcinoma context.

Cell Line Information: NCI-H1666

The table below consolidates the essential biological, genetic, and operational characteristics of the NCI-H1666 cell line to support informed experimental design and data interpretation.

Our Services

Alfa Cytology delivers a comprehensive NCI-H1666 xenograft program encompassing authenticated cell banking, mycoplasma and sterility verification, tumor implantation, longitudinal monitoring, and multi-modal endpoint analysis. Our standardized workflows—refined across numerous chaperone- and MAPK-pathway lung cancer studies—ensure consistent engraftment, reproducible tumor growth curves, and pharmacologically meaningful readouts that strengthen your preclinical development decisions.

Workflow of NCI-H1666 Xenograft Model Construction

Construction of the NCI-H1666 xenograft model at Alfa Cytology follows a regimented, IACUC-approved pipeline that prioritizes genetic authenticity, sterile technique, and reproducible tumor growth. Each operational phase is documented under GLP-aligned quality systems to ensure complete auditability from cell thaw to final dataset delivery.

1. Master Cell Bank Revival & Expansion: NCI-H1666 cells are revived from authenticated, low-passage master stocks stored under liquid nitrogen and expanded in RPMI-1640 supplemented with 5% FBS. Each batch undergoes mycoplasma PCR screening, STR profiling confirmation against the published ATCC profile, and viability assessment prior to harvest.
2. Pre-Implantation Cell Preparation: Cultures in logarithmic growth phase are dissociated with trypsin-EDTA, neutralized with complete medium, and pelleted by centrifugation at 125×g for 5–10 minutes. The pellet is washed twice with sterile PBS to eliminate serum traces, then resuspended in ice-cold PBS at a concentration of 5×10⁷ cells/mL for a final inoculum of 5×10⁶ cells per 100 μL injection volume.
3. Matrigel Mixing & Injection Preparation: High-concentration, phenol-red-free Matrigel is thawed at 4°C overnight and maintained on ice. The cell suspension is mixed 1:1 with cold Matrigel immediately before injection to promote cell retention, angiogenesis, and standardized engraftment kinetics. The mixture is kept on ice at all times to prevent premature polymerization.
4. Subcutaneous Tumor Implantation: Six- to eight-week-old female SCID or athymic nude mice are acclimatized for a minimum of seven days. Under aseptic conditions, 200 μL of the cell-Matrigel suspension is injected subcutaneously into the right flank using a 26-gauge needle. Mice are monitored daily for general health and injection-site integrity.
5. Tumor Establishment & Cohort Randomization: Tumors are monitored by palpation beginning on day 7 post-implantation. Once tumors become palpable and reach a mean volume of 80–120 mm³—typically 10–14 days after injection—mice are stratified by tumor size and randomized into vehicle control and treatment cohorts (n = 8–10 per group).
6. Dosing, Monitoring & Endpoint Analysis: Test agents are administered according to protocol-specified routes (PO, IP, IV, or SC) and schedules. Tumor dimensions and body weights are recorded twice weekly; tumor volume is calculated as (width)² × length / 2. Studies conclude at a humane endpoint (typically 2,000 mm³ or 21–28 days post-treatment), at which point tumors are excised, weighed, and allocated for histopathology (H&E), immunohistochemistry (p-ERK, p-MEK, p-BRAF, Ki-67, CD31, TUNEL), and molecular profiling (qPCR, Western blot, RNA-seq). Serum is collected for pharmacokinetic correlation where applicable.

Fig 2. NCI-H1666 xenograft model construction workflow.

Case Study

In a recent preclinical evaluation, Alfa Cytology established the NCI-H1666 subcutaneous xenograft to assess the anti-tumor efficacy of a novel HSP90 inhibitor in a BRAF-mutant, wild-type EGFR bronchoalveolar carcinoma context. Following robust tumor engraftment in female SCID mice, animals were randomized into vehicle control and treatment arms (n = 8–10 per group) once mean tumor volume reached approximately 100 mm³. The test compound was administered via intravenous injection on a weekly schedule for 3 weeks at escalating dose levels. Longitudinal monitoring revealed dose-dependent tumor growth inhibition in treated animals relative to vehicle controls, with the highest dose cohort demonstrating sustained suppression and measurable tumor regression throughout the treatment window. At study termination, harvested tumors underwent comprehensive histopathological review and biomarker analysis, including p-ERK and p-MEK immunostaining to confirm downstream MAPK pathway modulation, Ki-67 quantification to evaluate proliferative inhibition, and TUNEL assay to assess apoptotic induction. Body weight records remained stable across all cohorts, indicating an acceptable tolerability profile. Complete pharmacodynamic datasets, including individual tumor growth trajectories and immunohistochemistry images, are available for disclosure under a confidentiality agreement.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your NCI-H1666 xenograft program provides access to a purpose-built infrastructure optimized for chaperone- and MAPK-pathway lung cancer preclinical research. Our service architecture combines scientific depth with operational agility to accelerate your compound evaluation timeline.

• Authenticated NCI-H1666 master and working cell banks are maintained under liquid nitrogen with biannual STR confirmation against the ATCC reference profile and documented mycoplasma negativity, ensuring genetic stability across every study.
• Standardized implantation protocols with Matrigel support yield consistent tumor engraftment and predictable growth kinetics in this loosely adherent bronchoalveolar model, enabling precise power calculations and efficient cohort sizing.
• Flexible study architectures accommodate single-agent HSP90 inhibitor, SHP2 inhibitor, BRAF/MEK combination, and EGFR-targeted ADC evaluation designs, with dosing routes and schedules tailored to your compound properties.
• On-site histopathology and IHC capabilities—including p-ERK, p-MEK, p-BRAF, Ki-67, CD31, and TUNEL—deliver rapid turnaround without external vendor coordination or sample custody interruptions.
• Secure client data portals provide real-time visibility into tumor measurements, body weights, and study milestones, with automated notifications at predefined protocol checkpoints.
• Each engagement is supported by a dedicated scientific project manager who coordinates weekly progress reports, interim data presentations, and adaptive protocol amendments aligned with your evolving research priorities.

Contact Us

If your research pipeline targets the BRAF-mutant bronchoalveolar carcinoma landscape—whether advancing an HSP90-directed strategy, exploring SHP2 inhibition, or evaluating BRAF/MEK combination blockade in a wild-type EGFR and KRAS context—Alfa Cytology offers the NCI-H1666 xenograft expertise to advance your preclinical objectives with scientific rigor. Reach out to our scientific team today to discuss your study parameters, request a customized proposal, or arrange a consultation with our oncology model specialists. We are committed to converting your therapeutic hypothesis into robust, publication-ready preclinical evidence.

For research use only. Not intended for any clinical use.